welcome
Reuters

Reuters

Health

Health

Analysis-Pharma companies expected to absorb any tariff hit in short term

Reuters
Summary
Nutrition label

79% Informative

U.S. tariffs on pharmaceuticals could eventually mean higher prices for brand-name medicines.

But in the near term the costs would likely be absorbed by drugmakers rather than patients.

The Trump administration has opened a national security investigation into pharmaceuticals.

The industry has been lobbying for phased-in tariffs.

VR Score

91

Informative language

99

Neutral language

34

Article tone

formal

Language

English

Language complexity

63

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links